(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 112.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Autolus Therapeutics's revenue in 2025 is $29,934,000.On average, 4 Wall Street analysts forecast AUTL's revenue for 2025 to be $21,157,709,892, with the lowest AUTL revenue forecast at $17,618,561,408, and the highest AUTL revenue forecast at $25,850,315,250. On average, 4 Wall Street analysts forecast AUTL's revenue for 2026 to be $48,784,519,061, with the lowest AUTL revenue forecast at $34,731,986,418, and the highest AUTL revenue forecast at $78,099,197,058.
In 2027, AUTL is forecast to generate $76,615,724,833 in revenue, with the lowest revenue forecast at $56,609,874,968 and the highest revenue forecast at $118,294,534,361.